<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>New Data Paves the Way for Weight-Loss Drugs in Children as Young as 6 — Live Feed</title><link>https://www.live-feeds.com/feed/new-data-paves-the-way-for-weight-loss-drugs-in-children-as-young-as-6</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/new-data-paves-the-way-for-weight-loss-drugs-in-children-as-young-as-6/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>Weight-Loss Drugs Show Efficacy in Children as Young as 6</title><link>https://www.live-feeds.com/feed/new-data-paves-the-way-for-weight-loss-drugs-in-children-as-young-as-6</link><guid isPermaLink="false">https://www.live-feeds.com/feed/new-data-paves-the-way-for-weight-loss-drugs-in-children-as-young-as-6#u209174</guid><pubDate>Thu, 19 Nov 2026 20:00:59 +0000</pubDate><description>New clinical trial data demonstrate that Novo Nordisk&amp;#039;s Wegovy injection lowers body mass index and obesity rates in children as young as six years old. Additional real-world data indicate that Novo&amp;#039;s Wegovy pill helps patients lose about six percent of their weight in three months. While these findings pave the way for expanding GLP-1 weight-loss medications to elementary-age patients, doctors remain divided regarding how broadly these treatments should be administered to younger children.Why it mattersThe expansion of GLP-1 therapies into younger demographics arrives amid shifting </description></item>
</channel></rss>